Unfortunately, researchers have yet to find any significant alteration within PTEN (phosphatase and tendon homolog that is a tumor suppressor) through the combination of treatment from PI3K and Herceptin applied to the HCC1569 breast cancer cell line [75], so more studies are required to find better concentrations or methodologies. This evidence concerns the gene PIK3CA and neoplasm.